Mr. Hugh Rogers reports

BIONXT SOLUTIONS ANNOUNCES CLOSING OF THIRD TRANCHE OF CONVERTIBLE DEBENTURE PRIVATE PLACEMENT

Further to the news releases dated Oct. 28, 2024, Nov. 12, 2024, and Nov. 29, 2024, Bionxt Solutions Inc. has closed the third tranche of its previously announced non-brokered private placement of unsecured convertible debentures, pursuant to which it raised the principal amount of $1.4-million. The company has closed an aggregate principal amount of $2.11-million, comprising a first tranche of $425,000, a second tranche of $285,000 and a third tranche of $1.4-million. The company intends to close one or more tranches of the offering in the future.

The convertible debenture bears interest at a rate of 8 per cent per annum from the date of issue, and matures two years following the issue date. The principal amount and any accrued and unpaid interest on the debenture may be convertible at the election of the holder into common shares in the capital of the company at a conversion price of 25 cents per common share. Conversion of the debentures may be forced at the option of the company if the 15-day volume-weighted average price of the common shares on the Canadian Securities Exchange exceeds 62.5 cents.

In accordance with applicable securities laws, all securities issued under the offering will be subject to a four-month-and-one-day hold period from the issue date.

In connection with the offering, the company paid a cash fee of $112,000 and issued 448,000 finder warrants to Canaccord Genuity Corp. Each finder warrant entitles the holder thereof to purchase one common share at an exercise price of 25 cents for a period of 24 months from the date of issuance.

The company intends to use the net proceeds from the offering for product development, intellectual property filings and general working capital.

About Bionxt Solutions Inc.

Bionxt is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

We seek Safe Harbor.